Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.

摘要: Elevated high-sensitivity C-reactive protein (hs-CRP) levels are associated with an increased risk of atherosclerotic coronary heart disease (CHD). The addition the bile acid sequestrants, such as colesevelam hydrochloride (HCl), to statins further reduces low-density lipoprotein (LDL) cholesterol levels. However, effects approved cholesterol-lowering sequestrants on hs-CRP have not previously been reported. Three randomized, double-blind, placebo-controlled, parallel, 6-week clinical trials similar design investigated efficacy adding HCl stable simvastatin, atorvastatin, or pravastatin treatment in 204 patients primary hypercholesterolemia. end point was mean percent change LDL Secondary points included other lipid parameters and A pooled analysis showed that statin therapy significantly lowered (21 mg/dl 16% reduction from baseline, p = 0.0013, 11 9% compared placebo, 0.0003). Four times many receiving plus a achieved target <100 placebo (39% vs 10%, respectively, <0.0001). incidence mild gastrointestinal adverse slightly higher group than group. Finally, differences were significant changes (median -23%, 0.0069). In conclusion, this is first report suggesting sequestrant, specifically HCl, decreases when added therapy.